Matrine could simultaneously inhibit c-Myc transcription and translation, and inhibit the downstream ribosome biogenesis and nucleotide metabolism, thereby killing myeloid leukemia cell lines, suggesting that matrine can be used as an inhibitor of c-Myc to treat c-Myc-driven leukemia. Here, MYC is linked to leukemia.